Yahoo · Nov 12, 2026
ICON: 3 Key Takeaways for Long-Term Investors
AI-driven efficiency gains and debt refinancing position the company to convert record bookings into margin expansion.

NASDAQ · ICLR
Healthcare · Medical - Diagnostics & Research
$195.16
Down-$4.80 (-2.46%)
Updated Nov 20, 2026, 1:45 AM
SID Score
7.4/10
Composite research score
Smart Money
56/100
Neutral
Price performance · ICLR
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 18, 2026
ICLR closed at $195.16 after 20 trading sessions, up 5.25% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 18, 2026 | $193.75 | $198.11 | $192.105 | $195.16 | 548.49K |
| Nov 17, 2026 | $191.24 | $197.47 | $190.435 | $195.02 | 662.79K |
| Nov 16, 2026 | $195.47 | $196.32 | $188.55 | $191.40 | 826.22K |
| Nov 13, 2026 | $200.56 | $200.56 | $194.39 | $194.65 | 966.54K |
| Nov 12, 2026 | $198.43 | $200.75 | $194.06 | $200.51 | 779.98K |
| Nov 11, 2026 | $204.32 | $208.38 | $199.41 | $199.70 | 647.32K |
| Nov 10, 2026 | $206.30 | $206.30 | $200.8675 | $204.63 | 617.11K |
| Nov 9, 2026 | $206.10 | $210.58 | $203.845 | $207.59 | 1.04M |
| Nov 6, 2026 | $200.87 | $208.26 | $200.535 | $204.74 | 1.38M |
| Nov 5, 2026 | $203.41 | $206.4299 | $197.21 | $201.65 | 1.48M |
| Nov 4, 2026 | $205.17 | $209.715 | $202.09 | $203.11 | 1.26M |
| Nov 3, 2026 | $204.45 | $209.735 | $203.06 | $203.77 | 1.1M |
| Nov 2, 2026 | $206.00 | $211.00 | $202.84 | $205.14 | 778.52K |
| Oct 30, 2026 | $211.52 | $212.905 | $207.01 | $211.36 | 2.58M |
| Oct 29, 2026 | $211.53 | $219.04 | $207.535 | $215.48 | 1.8M |
| Oct 28, 2026 | $199.19 | $214.94 | $195.80 | $214.16 | 3.95M |
| Oct 27, 2026 | $182.23 | $186.99 | $181.735 | $182.98 | 890.73K |
| Oct 26, 2026 | $182.08 | $185.59 | $179.16 | $183.78 | 1.07M |
| Oct 23, 2026 | $184.25 | $185.57 | $179.89 | $185.27 | 1.02M |
| Oct 22, 2026 | $180.09 | $190.56 | $180.09 | $185.43 | 1.02M |
The latest Smart Investors Daily articles mentioning ICLR.
Company
Market Activity
Research & News
ICLR research
Company profile and research snapshot.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | Baird | Outperform | — |
| Oct 29, 2026 | RBC Capital | Outperform | — |
| Oct 29, 2026 | Truist Securities | Buy | — |
| Oct 29, 2026 | Barclays | Equal-Weight | — |
| Oct 29, 2026 | UBS | Neutral | — |
No generated briefing is available yet.
Yahoo · Nov 12, 2026
AI-driven efficiency gains and debt refinancing position the company to convert record bookings into margin expansion.
Yahoo · Nov 10, 2026
DUBLIN, November 10, 2026--ICON to Participate at Upcoming Investor Conferences
Yahoo · Nov 5, 2026
DUBLIN, November 05, 2026--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced the release of AI-directed video production capabilities within its FIRECREST site & patient communications platform.
Benzinga · Nov 4, 2026
Revealing a significant insider sell on November 3, Edward Barry Balfe, Chief Executive Officer at Icon (NASDAQ:ICLR), as per the latest SEC filing. What Happened: After conducting a thorough analysis, Balfe sold 5,175
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning ICLR.